OOIR: Observatory of International Research

Papers

(The H4-Index of Lancet HIV is 40. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
Tackling cancer risk in adolescents and young adults with HIV	221
Invest in HIV now to reap future rewards	192
Inherited fear: 40 years of HIV/AIDS in the UK	147
The time to end the war on drugs is long overdue	137
Rapid access to antiretroviral therapy, receipt of naltrexone, and strengths-based case management versus standard of care for HIV viral load suppression in people with HIV who inject drugs in Russia	129
Lenacapavir plus two bNAbs: feasible, with some caveats	120
Call for justice-informed HIV cure trials with ATIs	119
A new initiative to track HIV resource allocation	107
The power of peers at prison exit	101
Improving outcomes for children in families with HIV	101
Trauma-informed HIV prevention for forcibly displaced adolescents and young adults	99
Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial	90
Highlights of HIV Drug Therapy 2022	90
Changes in bodyweight after initiating antiretroviral therapy close to HIV-1 seroconversion: an international cohort collaboration	82
Optimising HIV spending in eastern Europe and central Asia	73
Reflections on a decade of The Lancet HIV	72
Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind,	72
PEPFAR reauthorisation hangs in the balance	72
UNAIDS strategy aligns HIV priorities with development goals	71
Empowering women: addressing HIV vertical transmission in the Philippines	70
Dolutegravir for children with HIV-associated tuberculosis	69
Gone but not forgotten	69
Zvandiri—when medicines alone are not enough	67
How much could long-acting PrEP cost in South Africa?	65
AIDS activism from the beginning	59

Combination HIV prevention reduces orphanhood in Uganda	55
Helping hospitals heal people with HIV and tuberculosis	55
Community mobilisation to achieve HIV testing and care goals	52
Evidence supports use of on-demand PrEP for HIV prevention	51
HIV and mental health services for female sex workers	51
Transitioning youth living with HIV to adult HIV care	50
The Australian AIDS crisis through the eyes of volunteers	47
Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial	45
Lymphomas included in the AIDS case definition: an update 30 years later	44
HIV-related CNS infections: translating DREAMM into reality	44
The Háttér Society: supporting LGBTQ people in Hungary	41
Anything but pro-life	41
Ageing with HIV: is the virus or the treatment guilty?	41
UK HIV transmission drops in the wake of COVID-19	41
Integrase strand-transfer inhibitor use and cardiovascular events in adults with HIV: an emulation of target trials in the HIV-CAUSAL Collaboration and the Antiretroviral Therapy Cohort Collaboration	40
Marking 40 years of the HIV/AIDS response	40